Abstracts
Vol. 2 No. 13 (2006)
https://doi.org/10.4081/hmr.v2i13.483

Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 10 June 2009
338
Views
1292
Downloads

Authors

SJ Proctor
support@pagepress.org
J Wilkinson
Until the advent of anti-CD20 antibody therapy, the mainstay of treatment in non-Hodgkin’s lymphoma (NHL) was standard chemotherapy. The combination of antibodies with chemotherapy has enhanced event-free and overall survival in both diffuse large B cell NHL and follicular NHL.1 With this example of combined chemo/ immunotherapy to enhance clinical response, it has been considered of interest to attempt a similar approach for T cell NHL and Hodgkin’s lymphoma (HL).

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma. (2009). Hematology Meeting Reports, 2(13). https://doi.org/10.4081/hmr.v2i13.483